S&P 500   3,004.52 (+0.28%)
DOW   26,833.95 (+0.17%)
QQQ   192.22 (+0.19%)
AAPL   243.18 (+1.34%)
FB   186.19 (+2.11%)
MSFT   137.24 (+0.64%)
GOOGL   1,257.63 (+1.32%)
AMZN   1,762.17 (-0.20%)
CGC   21.75 (+2.84%)
NVDA   195.09 (-0.27%)
MU   44.66 (+0.00%)
BABA   169.92 (+0.02%)
GE   9.14 (+0.88%)
TSLA   254.68 (-0.35%)
AMD   31.36 (-0.48%)
T   37.74 (-1.13%)
F   9.21 (+1.54%)
ACB   3.67 (+2.51%)
PRI   125.75 (-0.04%)
NFLX   271.27 (+1.72%)
BAC   31.42 (+0.71%)
GILD   66.58 (+1.09%)
DIS   131.13 (-0.96%)
S&P 500   3,004.52 (+0.28%)
DOW   26,833.95 (+0.17%)
QQQ   192.22 (+0.19%)
AAPL   243.18 (+1.34%)
FB   186.19 (+2.11%)
MSFT   137.24 (+0.64%)
GOOGL   1,257.63 (+1.32%)
AMZN   1,762.17 (-0.20%)
CGC   21.75 (+2.84%)
NVDA   195.09 (-0.27%)
MU   44.66 (+0.00%)
BABA   169.92 (+0.02%)
GE   9.14 (+0.88%)
TSLA   254.68 (-0.35%)
AMD   31.36 (-0.48%)
T   37.74 (-1.13%)
F   9.21 (+1.54%)
ACB   3.67 (+2.51%)
PRI   125.75 (-0.04%)
NFLX   271.27 (+1.72%)
BAC   31.42 (+0.71%)
GILD   66.58 (+1.09%)
DIS   131.13 (-0.96%)
Log in

Cerus Stock Price, News & Analysis (NASDAQ:CERS)

$4.41
-0.01 (-0.23 %)
(As of 10/23/2019 04:00 PM ET)
Today's Range
$4.34
Now: $4.41
$4.47
50-Day Range
$4.35
MA: $4.87
$5.46
52-Week Range
$4.29
Now: $4.41
$6.88
Volume756,600 shs
Average Volume858,343 shs
Market Capitalization$618.82 million
P/E RatioN/A
Dividend YieldN/A
Beta1.64
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:CERS
CUSIP15708510
Phone925-288-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$60.91 million
Book Value$0.62 per share

Profitability

Net Income$-57,560,000.00

Miscellaneous

Employees240
Market Cap$618.82 million
Next Earnings Date10/30/2019 (Confirmed)
OptionableOptionable

Receive CERS News and Ratings via Email

Sign-up to receive the latest news and ratings for CERS and its competitors with MarketBeat's FREE daily newsletter.


Cerus (NASDAQ:CERS) Frequently Asked Questions

What is Cerus' stock symbol?

Cerus trades on the NASDAQ under the ticker symbol "CERS."

How were Cerus' earnings last quarter?

Cerus Co. (NASDAQ:CERS) announced its quarterly earnings data on Thursday, August, 1st. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.01. The biotechnology company had revenue of $18.20 million for the quarter, compared to analysts' expectations of $17.55 million. Cerus had a negative net margin of 98.69% and a negative return on equity of 85.73%. The firm's quarterly revenue was up 18.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.10) earnings per share. View Cerus' Earnings History.

When is Cerus' next earnings date?

Cerus is scheduled to release their next quarterly earnings announcement on Wednesday, October 30th 2019. View Earnings Estimates for Cerus.

How can I listen to Cerus' earnings call?

Cerus will be holding an earnings conference call on Wednesday, October 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Cerus issued on next quarter's earnings?

Cerus updated its FY 2019 earnings guidance on Thursday, August, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $72-75 million, compared to the consensus revenue estimate of $93.48 million.

What price target have analysts set for CERS?

3 brokerages have issued twelve-month target prices for Cerus' shares. Their predictions range from $7.00 to $9.00. On average, they expect Cerus' stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 81.4% from the stock's current price. View Analyst Price Targets for Cerus.

What is the consensus analysts' recommendation for Cerus?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cerus.

Has Cerus been receiving favorable news coverage?

Media coverage about CERS stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cerus earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Cerus.

Are investors shorting Cerus?

Cerus saw a drop in short interest in September. As of September 30th, there was short interest totalling 7,090,000 shares, a drop of 5.6% from the August 30th total of 7,510,000 shares. Based on an average daily trading volume, of 859,900 shares, the short-interest ratio is presently 8.2 days. Currently, 5.3% of the company's stock are short sold. View Cerus' Current Options Chain.

Who are some of Cerus' key competitors?

What other stocks do shareholders of Cerus own?

Who are Cerus' key executives?

Cerus' management team includes the folowing people:
  • Mr. William M. Greenman, Pres, CEO & Director (Age 52)
  • Dr. Laurence M. Corash, Co-Founder, Chief Scientific Officer, Sr. VP & Corp. Director (Age 75)
  • Mr. Kevin D. Green, VP of Fin. & CFO (Age 47)
  • Ms. Chrystal N. Menard, Chief Legal Officer and Gen. Counsel (Age 48)
  • Dr. Richard J. Benjamin, Chief Medical Officer (Age 59)

Who are Cerus' major shareholders?

Cerus' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (1.44%), Stephens Inc. AR (0.67%), First Midwest Bank Trust Division (0.60%), State of New Jersey Common Pension Fund D (0.30%) and Envestnet Asset Management Inc. (0.02%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson and William Mariner Greenman. View Institutional Ownership Trends for Cerus.

Which major investors are selling Cerus stock?

CERS stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC and First Midwest Bank Trust Division. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson and William Mariner Greenman. View Insider Buying and Selling for Cerus.

Which major investors are buying Cerus stock?

CERS stock was bought by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Stephens Inc. AR and Envestnet Asset Management Inc.. Company insiders that have bought Cerus stock in the last two years include Laurence M Corash and William Mariner Greenman. View Insider Buying and Selling for Cerus.

How do I buy shares of Cerus?

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cerus' stock price today?

One share of CERS stock can currently be purchased for approximately $4.41.

How big of a company is Cerus?

Cerus has a market capitalization of $618.82 million and generates $60.91 million in revenue each year. The biotechnology company earns $-57,560,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. Cerus employs 240 workers across the globe.View Additional Information About Cerus.

What is Cerus' official website?

The official website for Cerus is http://www.cerus.com/.

How can I contact Cerus?

Cerus' mailing address is 2550 STANWELL DRIVE, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]


MarketBeat Community Rating for Cerus (NASDAQ CERS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  502 (Vote Outperform)
Underperform Votes:  346 (Vote Underperform)
Total Votes:  848
MarketBeat's community ratings are surveys of what our community members think about Cerus and other stocks. Vote "Outperform" if you believe CERS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CERS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel